Riik: Austraalia
keel: inglise
Allikas: Department of Health (Therapeutic Goods Administration)
ondansetron hydrochloride dihydrate, Quantity: 10 mg (Equivalent: ondansetron, Qty 8 mg)
Aspen Pharmacare Australia Pty Ltd
Ondansetron hydrochloride
Injection, solution
Excipient Ingredients: water for injections; citric acid monohydrate; sodium chloride; sodium citrate dihydrate
Intravenous
4mL x 5 (glass pre-filled syringes)
(S4) Prescription Only Medicine
For the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. For the prevention and treatment of post-operative nausea and vomiting. INDICATIONS AS AT 25 July 1994: . For the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy; . For the prevention and treatment post-operative nausea and vomiting.
Visual Identification: Clear colourless liquid practically free of particles.; Container Type: Syringe; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store below 30 degrees Celsius
Registered
2006-02-01
1 AUSTRALIAN PRODUCT INFORMATION ZOFRAN (ONDANSETRON HYDROCHLORIDE DIHYDRATE) INJECTIONS, TABLETS AND ORAL LIQUID, ZOFRAN (ONDANSETRON) SUPPOSITORIES AND ZOFRAN ZYDIS (ONDANSETRON) WAFERS 1 NAME OF THE MEDICINE Ondansetron hydrochloride dihydrate is the therapeutically active ingredient in Zofran injections, Zofran tablets and Zofran oral liquid. Ondansetron is the therapeutically active ingredient in Zofran suppositories and in Zofran Zydis wafers. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Zofran 4 mg and 8 mg tablets contain 4 and 8 mg of ondansetron (as ondansetron hydrochloride dihydrate) and the following excipients: lactose monohydrate, microcrystalline cellulose, pregelatinised maize starch, magnesium stearate, hypromellose, titanium dioxide and iron oxide yellow. Excipients with known effect: sugars as lactose Zofran 24 mg tablets contain 24 mg of ondansetron (as ondansetron hydrochloride dihydrate) and the following excipients: lactose, microcrystalline cellulose, pregelatinised maize starch, magnesium stearate and Opadry Pink YS-1-14593-A (ARTG PI No: 3522). Excipients with known effect: sugars as lactose Zofran oral liquid contains 0.8 mg/mL of ondansetron (as ondansetron hydrochloride dihydrate) and the following excipients: citric acid, sodium citrate dihydrate, sodium benzoate, sorbitol solution (70 percent) (crystallising), purified water and Strawberry Flavouring Liquid SC887891 (ARTG PI No: 140281). Excipients with known effect: benzoates and sorbitol (12.6g per recommended maximum daily dose) which may have a laxative effect or cause diarrhoea Zofran Zydis wafers contain 4 and 8 mg of ondansetron and the following excipients: gelatin, mannitol, aspartame, sodium methyl hydroxybenzoate, sodium propyl hydroxybenzoate and Strawberry Flavouring Liquid SC887891 (ARTG PI No: 140281). Excipients with known effect: aspartame, hydroxybenzoates and sulphites. Each 2 mL Zofran injection contains 4 mg of ondansetron (as ondansetron hydrochloride dihydrate) and the following excipients: citric acid monohydr Lugege kogu dokumenti